Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

3.360 -0.100 (-2.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 Next >
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Enters into Agreement with Bradley L. Radoff and Michael Torok 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Top movers in Wednesday's pre-market session
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
From On Behalf of The Radoff-JEC Group
Via Business Wire
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
No Shareholder Action is Required at this Time 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial
Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug. 
Via Benzinga
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For March 6, 2025
Via Benzinga
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir. 
Via Benzinga
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy. 
Via Benzinga
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.